Anisur Rahman

Q: What Schools Are Affiliated With Anisur Rahman

Anisur Rahman is affiliated with the following schools: University of California, Berkeley, University College London, Stanford University, Dhaka Medical College and Hospital

Anisur Rahman's AcademicInfluence.com Rankings

Anisur Rahman

Computer Science

#5488

World Rank

#5796

Historical Rank

Computational Linguistics

#778

World Rank

#791

Historical Rank

Machine Learning

#1483

World Rank

#1505

Historical Rank

Artificial Intelligence

#1717

World Rank

#1749

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Anisur Rahman's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Anisur Rahman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Anisur Rahman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Systemic lupus erythematosus (2006) (5367)
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2011) (3649)
Systemic lupus erythematosus. (2008) (987)
Mortality in systemic lupus erythematosus. (1987) (584)
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force (2014) (526)
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. (2005) (473)
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2014) (377)
An international cohort study of cancer in systemic lupus erythematosus. (2005) (372)
Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus (2005) (352)
The frequency and outcome of lupus nephritis: results from an international inception cohort study. (2016) (301)
14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. (2014) (294)
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) (2016) (259)
Fifty years of anti-ds DNA antibodies: are we approaching journey's end? (2007) (258)
Cancer risk in systemic lupus: an updated international multi-centre cohort study. (2013) (242)
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus (2009) (236)
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. (2014) (224)
B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. (2006) (211)
Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. (2009) (205)
Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. (2004) (185)
ORIGINAL ARTICLE: Antiphospholipid Antibodies Induce a Pro‐Inflammatory Response in First Trimester Trophoblast Via the TLR4/MyD88 Pathway (2009) (170)
Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality (2009) (170)
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus (2010) (167)
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients (2010) (159)
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study (2007) (151)
Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. (2007) (140)
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus (2011) (138)
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort (2012) (135)
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study (2012) (132)
In vivo inhibition of antiphospholipid antibody‐induced pathogenicity utilizing the antigenic target peptide domain I of β2‐glycoprotein I: proof of concept (2009) (129)
Numerical scoring for the BILAG-2004 index (2010) (124)
Effective Delivery Styles and Content for Self-management Interventions for Chronic Musculoskeletal Pain: A Systematic Literature Review (2012) (121)
Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study (2009) (117)
Can we identify how programmes aimed at promoting self-management in musculoskeletal pain work and who benefits? A systematic review of sub-group analysis within RCTs. (2011) (115)
Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial (2018) (115)
Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia (2005) (114)
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2012) (111)
Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. (2010) (108)
Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. (2006) (107)
Lymphoma risk in systemic lupus: effects of disease activity versus treatment (2012) (105)
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity (2009) (104)
Anti-C1q antibodies in systemic lupus erythematosus (2015) (103)
Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. (2015) (103)
Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. (2010) (102)
British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus (2007) (97)
Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial (2015) (97)
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA (2010) (97)
Novel Assays of Thrombogenic Pathogenicity in the Antiphospholipid Syndrome Based on the Detection of Molecular Oxidative Modification of the Major Autoantigen β2-Glycoprotein I (2011) (97)
Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study (2010) (94)
Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. (2006) (92)
Is α-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? (2004) (91)
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. (2006) (90)
Atherosclerosis in systemic lupus erythematosus. (2017) (88)
Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2014) (87)
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. (2013) (84)
The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? (2011) (84)
The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. (2011) (79)
Modulation of Trophoblast Angiogenic Factor Secretion by Antiphospholipid Antibodies is Not Reversed by Heparin (2011) (77)
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). (2014) (75)
Mechanisms of Disease Systemic Lupus Erythematosus (2008) (75)
Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome (2016) (74)
Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways (2010) (73)
"It struck me that they didn't understand pain": the specialist pain clinic experience of patients with chronic musculoskeletal pain. (2005) (72)
Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation. (2015) (71)
Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. (2008) (70)
The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS (2020) (70)
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2014) (69)
Hodgkin's lymphoma in systemic lupus erythematosus. (2007) (68)
Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort (2019) (67)
Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus (2017) (67)
The role of antibodies to DNA in systemic lupus erythematosus— A review and introduction to an international workshop on DNA antibodies held in London, May 1996 (1997) (66)
Autoantibodies, lupus and the science of sabotage. (2004) (64)
25‐Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort (2014) (63)
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register (2017) (63)
BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000 (2007) (60)
Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? (2004) (58)
Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis (2014) (57)
Factors affecting self-efficacy and pain intensity in patients with chronic musculoskeletal pain seen in a specialist rheumatology pain clinic. (2008) (56)
Acupuncture in the Treatment of Fibromyalgia in Tertiary Care – a Case Series (2007) (55)
Rheumatoid Arthritis and Incidence of Twelve Initial Presentations of Cardiovascular Disease: A Population Record-Linkage Cohort Study in England (2016) (55)
Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (55)
Treatment adherence and clinical outcome in systemic lupus erythematosus. (2007) (54)
2021 DORIS definition of remission in SLE: final recommendations from an international task force (2021) (53)
Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review (2013) (53)
How do antiphospholipid antibodies bind β2-glycoprotein I? (2003) (52)
Lung cancer in systemic lupus erythematosus. (2007) (52)
Systemic Lupus Erythematosus (2008) (51)
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus (2011) (51)
Race/ethnicity and cancer occurrence in systemic lupus erythematosus. (2005) (49)
Novel Three-Day, Community-Based, Nonpharmacological Group Intervention for Chronic Musculoskeletal Pain (COPERS): A Randomised Clinical Trial (2016) (48)
Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort (2015) (47)
Systematic analysis of sequences of anti-DNA antibodies—relevance to theories of origin and pathogenicity (2002) (47)
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends (2020) (47)
Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus (2014) (46)
Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus in Jamaica (2008) (46)
Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus (2016) (46)
Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2018) (45)
Decreased live births in women with systemic lupus erythematosus (2011) (44)
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients (2017) (43)
Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial (2018) (43)
Cardiac magnetic resonance imaging in patients with systemic lupus erythematosus (2008) (42)
Validation of MSAT: an instrument to measure medical students' self‐assessed confidence in musculoskeletal examination skills (2007) (42)
Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome (2014) (41)
A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. (2003) (41)
A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli (2006) (41)
Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality (2007) (39)
Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque (2016) (38)
Disturbances in peripheral blood B cell subpopulations in autoimmune patients (2002) (38)
Numerical scoring for the Classic BILAG index (2009) (38)
Common Patterns of B Cell Perturbation and Expanded V4-34 Immunoglobulin Gene Usage in Autoimmunity and Infection (2004) (38)
Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2019) (38)
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort (2018) (36)
Anti-DNA antibodies - overview of assays and clinical correlations (2002) (36)
Systemic lupus erythematosus—2005 annus mirabilis? (2006) (36)
Purified IgG from Patients with Obstetric but not IgG from Non-obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion (2014) (35)
Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. (2010) (35)
PEGylated drugs in rheumatology—why develop them and do they work? (2013) (34)
Arginine Residues Are Important in Determining the Binding of Human Monoclonal Antiphospholipid Antibodies to Clinically Relevant Antigens1 (2006) (34)
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2020) (33)
Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. (2016) (33)
Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies. (2002) (32)
Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. (1998) (32)
A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach (2016) (32)
Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review. (2012) (31)
The importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies. (2001) (30)
Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus (2019) (30)
Fibromyalgia (2014) (30)
Improving the self-management of chronic pain : COping with persistent Pain, Effectiveness Research in Self-management (COPERS) (2016) (29)
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus (2018) (29)
British pain clinic practitioners' recognition and use of the bio-psychosocial pain management model for patients when physical interventions are ineffective or inappropriate: results of a qualitative study (2010) (29)
Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome? (2009) (28)
Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. (2003) (28)
Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. (2008) (28)
American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort (2014) (28)
Methodological challenges and approaches to improving response rates in population surveys in areas of extreme deprivation (2012) (28)
Breast Cancer in Systemic Lupus Erythematosus (2013) (27)
The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin (2003) (27)
Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach (2020) (27)
15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report (2017) (27)
Important determinants of self-efficacy in patients with chronic musculoskeletal pain. (2004) (27)
Pain management for chronic musculoskeletal conditions: the development of an evidence-based and theory-informed pain self-management course (2013) (26)
How do antiphospholipid antibodies bind beta2-glycoprotein I? (2003) (26)
Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus (2019) (26)
IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study (2015) (25)
Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients (2017) (24)
Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome (2012) (24)
Thrombin Binding Predicts the Effects of Sequence Changes in a Human Monoclonal Antiphospholipid Antibody on Its In Vivo Biologic Actions 1 (2009) (24)
Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort (2019) (23)
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. (2020) (22)
Imaging Assessment of Cardiovascular Disease in Systemic Lupus Erythematosus (2011) (22)
Breast cancer in systemic lupus (2017) (22)
Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (21)
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort (2021) (20)
Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome. (2014) (19)
Molecular Cloning and Expression of the Fabs of Human Autoantibodies in Escherichia coli (2000) (19)
Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach (2018) (18)
Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. (2004) (18)
Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity (2005) (18)
Efficacy of an out-patient pain management programme for people with joint hypermobility syndrome (2014) (18)
Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome (2018) (18)
Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus? (2004) (17)
Evaluating the conformation of recombinant domain I of β2-glycoprotein I and its interaction with human monoclonal antibodies (2011) (17)
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays (2015) (17)
Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? (2007) (16)
Structure–function analysis and the molecular origins of anti-DNA antibodies in systemic lupus erythematosus (1999) (16)
A critical analysis of the tools to evaluate neuropsychiatric lupus (2017) (16)
Cytokines in systemic lupus erythematosus, London, UK (2003) (16)
Prevalence and impact of chronic widespread pain in the Bangladeshi and White populations of Tower Hamlets, East London (2013) (15)
Effectiveness and cost-effectiveness of a novel, group self-management course for adults with chronic musculoskeletal pain: study protocol for a multicentre, randomised controlled trial (COPERS) (2013) (15)
Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort (2019) (15)
Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK (2017) (15)
Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis (2011) (14)
Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort (2018) (14)
Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I (2018) (13)
Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort (2019) (13)
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach (2020) (13)
Impaired C3b/iC3b deposition on Streptococcus pneumoniae in serum from patients with systemic lupus erythematosus. (2009) (13)
New therapeutic avenues in SLE. (2015) (13)
Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. (2007) (13)
PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome (2018) (12)
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies (2021) (12)
The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally (2012) (12)
Sequences of monoclonal antiphospholipid antibodies: variations on an anti-DNA antibody theme. (1996) (12)
How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. (2009) (12)
The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis. (2016) (12)
Observer agreement for small bowel ultrasound in Crohn’s disease: results from the METRIC trial (2020) (12)
Systemic lupus erythematosus in 2013: Taking a closer look at biologic therapy for SLE (2014) (11)
Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events? (2019) (10)
Systemic Lupus Erythematosus: Genomics, Mechanisms, and Therapies (2012) (10)
Articular presentation of disseminated histoplasmosis (2007) (10)
Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort (2020) (10)
Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. (2021) (10)
Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort (2019) (9)
Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria (2021) (9)
A Comparison of 2019 EULAR/ACR SLE Classification Criteria with Two Sets of Earlier SLE Classification Criteria. (2020) (9)
Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome (2018) (9)
Can measuring urinary biomarkers improve the management of lupus nephritis? (2012) (9)
Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus (2021) (9)
Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. (2021) (9)
Domain I: the hidden face of antiphospholipid syndrome (2014) (9)
Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled trial protocol (2019) (8)
Anti-DNA antibodies—structure and function (2002) (8)
Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin (2014) (8)
Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome (2017) (8)
Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications. (2020) (8)
Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS (2015) (7)
Oxidation of β2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome (2017) (7)
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study (2022) (7)
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort (2022) (7)
Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2022) (7)
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. (2019) (7)
Red cell distribution width correlates with fatigue levels in a diverse group of patients with systemic lupus erythematosus irrespective of anaemia status. (2019) (7)
Outcomes of membranous and proliferative lupus nephritis – analysis of a single-centre cohort with more than 30 years of follow-up (2020) (6)
Molecular expression systems for anti-DNA antibodies—1 (2002) (6)
Association between Helicobacter Pylori Infection and Iron Deficiency Anemia: A Cross Sectional Study (2020) (6)
What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus? (2006) (6)
Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (6)
Clinical Evaluation Of Two Anti-Beta(2)glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome (2013) (6)
Origin and structure of autoantibodies and antigens in autoimmune rheumatic diseases (2008) (6)
Lupus Erythematosus: Clinical Evaluation and Treatment (2013) (6)
Flares in patients with systemic lupus erythematosus (2017) (6)
Acute Kidney Injury Following Ingestion of Averrhoa bilimbi Juice (2015) (6)
Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests (2017) (5)
Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study (2014) (5)
Do antiphospholipid antibodies have direct pathologic effects upon endometrial and trophoblast cells (2009) (5)
Pattern and Risk Factors of Diabetic Retinopathy among Type 2 Diabetic Patients: Experience in a Tertiary Care Hospital (2016) (5)
Management of cardiovascular risk factors in patients with systemic lupus erythematosus. (2008) (5)
Extended follow-up study (2015) (5)
Knowledge and Attitude of Bangladeshi Physicians towards Organ Donation and Transplantation (2016) (5)
Prediction of esophageal varices in liver cirrhosis by transient elastography and aspartate aminotransferase - to - platelet ratio index (APRI) (2018) (5)
Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort (2021) (5)
Mortality in SLE (2013) (5)
Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis (2017) (5)
Affinity purified antibodies directed against domain I of beta 2GPI are pathogenic in a mouse model of thrombosis (2013) (4)
Evaluating the Construct of Damage in Systemic Lupus Erythematosus (2021) (4)
Incidence and evaluation of open bite malocclusion and their management (2013) (4)
Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study (2020) (4)
Structure and function of autoantibodies and their role in autoimmune rheumatic diseases (2006) (4)
The role of in vitro expression systems in the investigation of antibodies to DNA. (1998) (4)
132 Going viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about mechanistic research in SLE and APSA (2018) (4)
Lessons from Sequence Analysis of Monoclonal Antiphospholipid Antibodies (2005) (3)
Chronic widespread pain: North and South. (2010) (3)
Essentials in rheumatology: disease managementI34. Metabolic bone diseases (2012) (3)
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications (2021) (3)
Fibromyalgia and hypermobility (2010) (3)
Elevated Combined Serum Free Light Chains Are Associated With Active Disease In Systemic Lupus Erythematosus (2013) (3)
Management of antiphospholipid syndrome (2020) (3)
Domain I of beta(2)-glycoprotein I ameliorates thrombosis induced by antiphospholipid antibodies in mice (2007) (3)
Does it take sugar? A clinical role for measuring the glycosylation of IgG? (1995) (3)
Serum Lipase Amylase Ratio in Predicting Aetiology, Severity and Outcome of Acute Pancreatitis in a Tertiary Care Hospital (2017) (3)
Menorrhagia: an underappreciated problem in pre-menopausal women with systemic lupus erythematosus (2019) (3)
Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset (2021) (3)
Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes (2019) (3)
PROFILING SUB-TYPES OF ANTI-B2 GLYCOPROTEIN I AND ANTI-DOMAIN I ANTIBODIES MAY DISTINGUISH BETWEEN DIFFERENT CLINICAL PHENOTYPES OF THE ANTIPHOSPHOLIPID SYNDROME (2011) (3)
Hepatitis B and Hepatitis C Virus Infection among End Stage Renal Disease Patients on Maintenance Hemodialysis, Their Family Members and Dialysis Staffs - A Prevalence Study (2017) (3)
Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus. (2021) (3)
Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation (2019) (3)
Antiphospholipid syndrome in pregnancy (2016) (3)
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. (2017) (3)
Mechanical Eye Trauma Epidemiology, Prognostic Factors, and Management Controversies—An Update (2021) (2)
Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease (2008) (2)
Secondary Antiphospholipid Syndrome (2015) (2)
Pegylated Recombinant Domain I of Beta-2-Glycoprotein I, a Potential Therapeutic Agent for Antiphospholipid Syndrome, Fully Retains Its Ability to Inhibit Binding of IgG or IgA Antibodies from Patients with APS to Beta-2-Glycoprotein I in Vitro (2015) (2)
Clinical and Biochemical Characteristics and Aetiology of Asymptomatic Raised Alanine Aminotransferase in Newly Detected Diabetes and Impaired Glucose Tolerance Patients (2016) (2)
Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage (2022) (2)
Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding (2021) (2)
Using serum metabolomics analysis to predict sub-clinical atherosclerosis in patients with SLE (2020) (2)
'Oh, Come All Ye Faithful': acquiring and maintaining a cohort. (2002) (2)
IgG Antiphospholipid Antibodies Enhance Stroke Damage: An in Vivo Ischemia/Reperfusion Study. (2014) (2)
323. Serum Anti-Apolipoprotein 1 Antibodies are Present in a Quarter of Patients with Systemic Lupus Erythematosus at the Time of Diagnosis and are Associated with Earlier Mortality (2013) (2)
The light chain of a human monoclonal antiphospholipid antibody has a dramatic influence on its functional properties in an in vivo mouse model (2006) (2)
S2A:5 Development and validation of a score to predict the risk of severe infection in sle (2018) (2)
Systemic lupus erythematosus into the next millennium: looking into the crystal ball (1999) (2)
Cancer Risk Factors in SLE: Multivariate Regression Analysis in 16,409 Patients (2014) (1)
AB0161 Antiphospholipid antibodies differentially regulate the expression & activity of the lysosomal proteases with effects upon monocyte autophagy (2017) (1)
Lymphoma risk in systemic lupus: effects of treatment versus disease activity (2012) (1)
Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis (2015) (1)
460 Flares in patients with systemic lupus erythematosus (2017) (1)
Predictors of Seizures in Systemic Lupus Erythematosus. (2011) (1)
Nitrated Nucleosome Levels in Patients with Systemic Lupus Erythematosus - Associations with Ethnicity and Autoantibody Status (2011) (1)
THU0256 Development and validation of a score to predict the risk of severe infection in sle (2017) (1)
Lung cancer in systemic lupus erythematosus (2012) (1)
A novel, efficient, expression system of domain I of human beta2 glycoprotein I in E-coli (2005) (1)
Nitrated Nucleosome Levels in Patients with Systemic Lupus Erythematosus-Associations with Disease Activity (2011) (1)
Is the Disease-Specific Lupusqol Sensitive To Changes of Disease Activity In Systemic Lupus Erythematosus Patients After Treatment of A Flare? (2014) (1)
Prevalence and impact of chronic widespread pain in the Bangladeshi and White populations of Tower Hamlets (2013) (1)
T524 EFFECTIVE DELIVERY STYLES AND CONTENT FOR CHRONIC PAIN SELF‐MANAGEMENT INTERVENTIONS: A SYSTEMATIC REVIEW (2011) (1)
Physical activity and menopausal symptoms (2019) (1)
A Survey of the Images Used on the Arthritis Research UK (ARUK) Osteomalacia Mind-Map in Relation to Cultural Background (2011) (1)
Purified IgG from patients with different clinical manifestations of the antiphospholipid syndrome have differential effects upon the NF-kappa B and p38MAPK signalling pathways in monocytes (2007) (1)
Maternal and Socio-Demographic Factors Associated with Birth Weight of Newborns Delivered at a Teaching Hospital of Dhaka City (2019) (1)
Nonalcoholic Fatty Liver Disease: Review (2012) (1)
Study on Gastrointestinal Evaluation of Iron Deficiency Anaemia Patients Attending at BIRDEM Hospital (2016) (1)
Compliance with Medication amongst Persons with Diabetes Mellitus during the COVID-19 Pandemic, Kerala, India: A Cross Sectional Study (2022) (1)
Keratoconus: early onset, the worst prognosis, eye rubbing and hand-dominance (2020) (1)
Declining Prevalence of Helicobacter Pylori Infection- A 13C Urea Breath Test (UBT) Based Study in Symptomatic (2019) (1)
What are the Potential Future Treatments in Antiphospholipid Syndrome (2012) (1)
Comparison of responsiveness of BILAG-2004, SLEDAI-2000 and BILAG Systems Tally (BST). (2021) (1)
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study (2017) (1)
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. (2017) (1)
The association between IgM and IgG antibodies against cardiolipin, beta 2-glycoprotein I and Domain I of beta 2-glycoprotein I with disease profile in patients with multiple sclerosis (2015) (1)
Induced Myopia among Readymade Garment (RGM) Workers (2021) (1)
Oral abstracts 3: RA Treatment and outcomesO13. Validation of jadas in all subtypes of juvenile idiopathic arthritis in a clinical setting (2012) (1)
Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events. (2022) (1)
Anti-Dense Fine Speckled 70 Autoantibodies in Systemic Lupus 1 The Prevalence and Determinants of Anti-DFS 70 Autoantibodies in an International Inception Cohort of Systemic Lupus Erythematosus Patients Running Head : Anti-Dense Fine Speckled 70 Autoantibodies in SLE 1 (2018) (1)
Diagnostic Accuracy of Serum Carbohydrate Antigen 19-9 in Determining Etiology of Obstructive Jaundice (2017) (1)
O59. The Cellular Effects of Anti-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome are Inhibited by Factor Xa Inhibitors, Hydroxychloroquine and Fluvastatin (2014) (1)
Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up (2022) (1)
Concurrent oral 2 - BHPR audit/service delivery and research OP10. Negotiating Targets for Treatment of RA with Patients (2011) (1)
Education Research [291–300] 291. Medical Students’ Attitude Towards Rheumatology Training at Fy1 And Fy2 Level: Results from a National Survey (2010) (1)
Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus (SLE) in Jamaica (2008) (1)
Muscle disorders111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study (2012) (1)
O6. Educating People About Osteomalacia: Development and Evaluation of a Multi-Language Interactive Tool (2014) (1)
O15. Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multi-Centre Register (2015) (1)
OP0006 ABNORMAL IRON METABOLISM AND MITOCHONDRIAL DYSFUNCTION: INVESTIGATING A NOVEL PATHOLOGICAL MECHANISM IN SYSTEMIC LUPUS ERYTHEMATOSUS (2020) (1)
207 The Ability of Recombinant Domain I of BETA-2-Glycoprotein I to Inhibit the Lupus Anticoagulant Effect of IGG from Patients with Anti-Phospholipid Syndrome is Enhanced by Pegylation (2016) (1)
Serum D-dimer is a Predictor of Severity and Outcome of Acute Pancreatitis (2019) (1)
Accidental Intramuscular Isoprenaline in Early Pregnancy: The Effects, Management and Outcome (2017) (1)
The Role of Transrectal Power Doppler Ultrasonography in Detection of Prostate Cancer (2021) (0)
064. FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (2017) (0)
Comparison of Outcome of Acute Viral Hepatitis between Diabetic and Non-diabetic Patients: A Tertiary Care Hospital Experience (2019) (0)
SOCIAL MEDIA USE AMONGST LUPUS PATIENTS (2018) (0)
Antiphospholipid syndrome and pregnancy (2021) (0)
CS-07 Economic evaluation of damage accrual in an international SLE inception cohort (2018) (0)
Serum metabolomic signatures can predict sub-clinical atherosclerosis in patients with SLE (2020) (0)
Vasculitis in lupus (2021) (0)
Systemic Lupus Erythematosus Patients With Atherosclerosis Are Characterised By a Distinct Invariant Natural Killer T Cell Phenotype and Altered CD1d-Mediated Lipid Antigen Presentation (2013) (0)
B cells: formation and structure of autoantibodies (1999) (0)
Combined use of metformin and Pioglitazone than metformin alone in Glucose intolerance patients with Nonalcoholic fatty liver disease showed significant Radiological and Biochemical improvement (2015) (0)
I099 Anti-phospholipid antibody syndrome (2019) (0)
SLE patients with atherosclerosis are characterised by a distinct iNKT cell phenotype and altered CD1d-mediated lipid antigen presentation (2013) (0)
603 Remission and low disease activity are associated with lower health care costs in an international inception cohort of patients with systemic lupus erythematosus (2022) (0)
CE-22 Cancer in systemic lupus erythematosus: results from the slicc inception cohort (2016) (0)
P162 Progression of subclinical cardiovascular disease in SLE: a five year follow up study (2020) (0)
P59 Predictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up (2020) (0)
PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome (2022) (0)
242 Baseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR) (2019) (0)
316. INCREASED RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO HAVE ASYMPTOMATIC PLAQUE ON VASCULAR ULTRASOUND: A 5 YEAR FOLLOW-UP STUDY (2017) (0)
P172 Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development (2020) (0)
Musculoskeletal and joint manifestations (2012) (0)
Assessment of Plaque Thickness and Area in Patients with SLE As Measures of Atherosclerosis - Associations with Disease Activity. (2014) (0)
260 How much Difference can we make by Standardized Assertive Management of Cardiovascular Risk Factors in Patients with Systemic Lupus Erythematosus: A Real-Life Clinic Study (2016) (0)
P42 Disease activity, impaired iron transport and failed sequestration: a novel mechanism for anaemia in systemic lupus erythematosus (2020) (0)
The appropriate management of SLE on the planet Mars (2005) (0)
Extent of vascular plaque predicts future cardiovascular events in patients with systemic lupus erythematosus (2022) (0)
Tolerance of Gastro-Intestinal Endoscopy without Sedation: An Experience in a Tertiary Level Hospital in Bangladesh (2018) (0)
1704 Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes (2021) (0)
259 Patients with Systemic Lupus Erythematosus who are Anti-Factor XA IGG Positive are Less Likely to have Atherosclerotic Plaque (2016) (0)
E024 Invariant natural killer T cells in RA and CVD (2019) (0)
Managing conventional cardiovascular risk factors in the lupus clinic – what can we achieve? (2018) (0)
322. Patients with Refractory Systemic Lupus Erythematosus Requiring Biologic Therapy Have Significant Levels of Baseline Co-Morbidities: Results from a National Multi-Centre Register (2014) (0)
PATTERNS OF IMMUNOGLOBULIN-G GLYCOSYLATION DISTINGUISH DIFFERENT CLINICAL PHENOTYPES OF ANTIPHOSPHOLIPID ANTIBODY POSITIVITY (2011) (0)
PROFILING ANTIBODIES TO SERUM PROTEASES IN PATIENTS WITH JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (2012) (0)
019 Modulation of monocyte autophagy as a therapeutic target in antiphospholipid syndrome (2019) (0)
Unusual presentations in patients with systemic lupus erythematosus: a result of disease activity or something else? (2020) (0)
O34. ANTI-PHOSPHOLIPID ANTIBODIES DIFFERENTIALLY REGULATE THE EXPRESSION AND ACTIVITY OF THE LYSOSOMAL PROTEASES WITH EFFECTS UPON MONOCYTE AUTOPHAGY (2017) (0)
Clinicopathological Profile and Outcome of Dengue Fever: A Tertiary Care Hospital Experience (2021) (0)
258 Patients with Systemic Lupus Erythematosus and Low Bone Mineral Density have no Significant Increased Subclinical Atherosclerosis Compared with Those with Systemic Lupus Erythematosus and Normal Bone Density (2016) (0)
Minimal Important Differences of the LupusQoL in patients with Systemic Lupus Erythematosus (2020) (0)
Reproductive issues in rheumatology: do you know how to advise your patients?I1. Is pregnancy a stress test for subsequent development of autoimmunity? (2012) (0)
P145 Membranous and proliferative lupus nephritis – analysis of a nationwide multicentre cohort (2020) (0)
The BILAG-2004 index is associated with development of new damage in SLE. (2022) (0)
i048 Adult SLE: survivors from childhood onset (2018) (0)
E89. The Disease-Specific Lupusqol is Sensitive to Change In Patients with Moderate or Severe Systemic Lupus Erythematosus after Treatment of a Flare (2015) (0)
I65 Fibromyalgia in a Bengali Population (2016) (0)
239. PEGYLATED DOMAIN I OF BETA-2-GLYCOPROTEIN I PREVENTS THROMBOSIS IN A MOUSE MODEL (2017) (0)
THE PODOCYTE IN LUPUS NEPHRITIS: HOW DO PATHOGENIC AUTOANTIBODIES EXERT THEIR EFFECT? (2009) (0)
022 Both Domain I and PEGylated Domain I of Beta-2-Glycoprotein I (β2GPI) are capable of inhibiting IgA APS antibody binding (2019) (0)
The Journal of Rheumatology Lupus Erythematosus: Results from the SLICC Inception Cohort Osteopontin and Disease Activity in Patients with Recent-onset Systemic (2019) (0)
Central sensitisation: causes, therapies, and terminology (2021) (0)
POS0111 DEVELOPMENT OF DAMAGE AND MORTALITY IN AN INCEPTION COHORT OF SLE PATIENTS (2021) (0)
Functional iron deficiency: a potential novel mechanism for fatigue in systemic lupus erythematosus (2018) (0)
IOP change after phacoemulsification with PCIOL implantation and its association with ocular biometric parameters (2021) (0)
Prevalance and association of Helicobater Pylori with gastro-duodenal mucosal lesions in patients with dyspepsia (2020) (0)
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS) RHEUMATOLOGY (2014) (0)
1124 Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach (2021) (0)
The role of anti-nucleosome antibodies in the pathogenesis of systemic lupus erythematosus (2005) (0)
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus (2015) (0)
Analysis and Follow-Up of Tidal and Pulmonary Function after Neonatal RDS Treatment and Related Influencing Factors (2021) (0)
Role of Insulin Sensitizers in Raised Alanine Aminotransferase in Non-alcoholic Fatty Liver Disease in Glucose Intolerance Patients: A Short-Term Experience with Metformin Plus Pioglitazone Versus Metformin Alone (2015) (0)
Factors Affecting Survival Trend in Colorectal Cancer- A Hospital Based Study (2019) (0)
Exposure of podocytes to immunoglobulin g from patients with lupus nephritis causes dephosphorylation of tubulin (2008) (0)
POS0106 BILAG-2004 LDA AND BST LDA ARE VALID TREAT TO TARGET IN SLE (2021) (0)
Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome (2017) (0)
Dengue: An emerging ocular problem (2020) (0)
P21 Investigation of possible pathogenic autoantibodies in membranous lupus nephritis (2020) (0)
Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally (2022) (0)
268 Different Patterns of Positivity for IgG Anti-Cardiolipin, Anti-β2-Glycoprotein I and Anti-Domain I Antibodies within the First Year of Disease in 501 Patients with Systemic Lupus Erythematosus: Associations with Different Clinical Outcomes (2016) (0)
Cross-talk between i NKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque # Short title : iNKT cells oppose pre-clinical plaque development (2016) (0)
Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis (2023) (0)
Factor Xa Reactive Antibodies In Patients With Systemic LUPUS Erythematosus and Antiphospholipid Syndrome Have Differential Effects Upon Coagulation Assays and Endothelial CELLS (2013) (0)
University of Birmingham Flares in patients with Systemic lupus erythematosus (SLE) (2020) (0)
P31 Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development (2020) (0)
138 Disease trends and phenotypes among different age groups: a study in lupus (2018) (0)
Sequence motifs in a human monoclonal Antiphospholipid antibody determine its ability to bind and affect the function of serine proteases (2008) (0)
140 Evaluating the prevalence of iron deficiency and anaemia in systemic lupus erythematosus (2018) (0)
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling. (2023) (0)
Personal exercise guide sheet (2015) (0)
Phase 1: development of the intervention – discussion (2016) (0)
Randomised controlled trial of the clinical effectiveness and cost-effectiveness of the COPERS intervention: methods (2016) (0)
A purified human autoantibody requires nucleosomes for binding to dsDNA (2005) (0)
Type 2 Diabetes Mellitus in Children and Adolescents: An update (2017) (0)
Qualitative study interview schedules (2015) (0)
Why Do Patients With Systemic Lupus Erythematosus Suffer Pain? (2021) (0)
Qualitative study consent form (2015) (0)
SLE and Antiphospholipid Syndrome [223–231] 223. Acid Disruption Biacore Analysis of Antibodies Against Rituximab in SLE Patients (2010) (0)
Identifying who is likely to respond to self-management programmes for chronic musculoskeletal pain (2016) (0)
Prevalence and impact of chronic widespread pain in the Bangladeshi and White populations of Tower Hamlets , East (2019) (0)
Back to the future: reflections on being a junior doctor again. (2023) (0)
Phase 2: evaluating the COPERS intervention – discussion (2016) (0)
Example of exercise diary (2015) (0)
Clinimetric study of outcome measures (2016) (0)
300. Attending a Pain Management Programme Reduces Hospital Investigations, Appointments and Interventions Over the Next Three Years (2014) (0)
Development of the new intervention (2016) (0)
CLINICAL AND ECHOCARDIOGRAPHIC EVALUATION OF CARDIOVASCULAR STATUS IN PRE DIALYSIS DIABETICS AND THOSE ON DIALYSIS: P 658 (2004) (0)
Fidelity, adherence and competence (2016) (0)
P170 Predictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up (2020) (0)
Results: number of participants in each analyses (2016) (0)
Disease Pattern of Musculoskeletal Disorders of the Patients Attending Outdoor of the Department of Physical Medicine and Rehabilitation, Sir Salimullah Medical College, Dhaka (2022) (0)
PS6:111 Forty years of a london lupus clinic – a retrospective analysis of drug use (2018) (0)
Arginine residues are important in determining the ability of human monoclonal antiphospholipid antibodies to bind clinically relevant antigens in the pathogenesis of the antiphospholipid syndrome (2006) (0)
Running Head : Economic Evaluation of Lupus Damage in an International Inception Cohort Title : Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach (2019) (0)
“The Accuracy, Sensitivity and Specificity of MRI (Magnetic Resonance Imaging) in Detection of Intraspinal Tumor.” (2020) (0)
Systematic review of predictors, mediators and moderators (2016) (0)
SARAH: strengthening and stretching for rheumatoid arthritis affecting the hand: a randomised controlled trial (2014) (0)
Purified IgG From Antiphospholipid Syndrome Patients with Pregnancy Morbidity Alone Inhibit Trophoblast Migration and Activate a TLR4 MyD88 Independent Pathway (2012) (0)
Systematic review (April 2009–September 2013): final value data by outcome and follow-up – forest plots (2016) (0)
Impairment measures scoring (2015) (0)
Intervention description and rationale (2015) (0)
What is the Antiphospholipid Syndrome ? (0)
The role of cardiac magnetic resonance imaging in the assessment of systemic lupus erythematosis (SLE) (2009) (0)
Development of the new self-management intervention (2016) (0)
Introduction to a systemic lupus erythematosus – biomarkers meeting held at University College London on 23rd and 24th February 2007 (2008) (0)
OP0252 NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY (2019) (0)
Unique monocyte transcriptomic profiles are associated with preclinical atherosclerosis in women with systemic lupus erythematosus (SLE) (2020) (0)
BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS CONNECTIVE TISSUE DISEASES (2015) (0)
Systematic review: evidence for the effectiveness of components and characteristics of pain and self-management programmes (2016) (0)
PS2:34 The effect of auto-antibody positivity on damage and death in a large cohort of patients with systemic lupus erythematosus: a 40-year follow-up study (2018) (0)
Serum Vitamin D Level and it’s Clinical Correlation with Rheumatological Diseases (2020) (0)
Autoimmune polyendocrine syndrome type 1 – a case report from Bangladesh (2017) (0)
Monoclonal Antiphospholipid Antibodies and their Sequences (2000) (0)
Monoclonal antiphospholipid antibodies and germline VH genes: comment on the article by Harmer et al. (1996) (0)
CE-21 The prevalence and determinants of ANTI-DFS70 antibodies in an international inception cohort of systemic lupus erythematosus (SLE) patients (2016) (0)
AB0407 Combined serum free light chains are associated with active disease in systemic lupus erythematosus (2013) (0)
ANTI-SERINE PROTEASE ANTIBODIES ARE DISTINGUISHABLE FROM ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (2010) (0)
114. Blood Pressure in SLE Patients (2015) (0)
THROMBOSIS AND HEMOSTASIS Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome (2014) (0)
I139 What’s New in Diagnosis of Antiphospholipid Syndrome? (2016) (0)
ANTI-APOA1 ANTIBODIES ASSOCIATE WITH DISEASE ACTIVITY IN LUPUS AND ARE LOWER IN PATIENTS TAKING HYDROXYCHLOROQUINE: A LONGITUDINAL ANALYSIS OF 398 SAMPLES (2012) (0)
Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients (2014) (0)
How to investigate: Very early inflammatory rheumatic diseases. (2019) (0)
P118 Orthopaedic surgical interventions in a cohort of patients with hypermobility related disorders, compared with chronic pain syndrome patients in a tertiary referral centre (2020) (0)
Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort (2017) (0)
BILAG-2004 index: A reliable tool for assessment of SLE activity (2005) (0)
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register (2014) (0)
103 Exploratory segregation of patients upon their levels of anti- mitochondrial antibodies (AMAs) reveals associations between AMAs and disease manifestations (2022) (0)
AB0675 RED CELL DISTRIBUTION WIDTH AND FATIGUE IN AXIAL SPONDYLOARTHRITIS: A SLEEPER SIGNAL (2020) (0)
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine (2022) (0)
Proteomic Analyses Of Monocyte Responses To IgG From Patients With Antiphospholipid Syndrome (2013) (0)
Revised BILAG-2004 index: a reliable tool for assessment of SLE disease activity. (2006) (0)
UNRAVELLING MONOCYTE RESPONSES TO ANTIPHOSPHOLIPID ANTIBODIES (2013) (0)
SAT0432 Membranous versus proliferative lupus nephritis: two different diseases? (2018) (0)
version of SELENA comparison of BILAG 2004 and the flare with systemic lupus erythematosus : a An assessment of disease flare in patients (0)
Ultrasound Assessment Of Both Carotid and Femoral Arteries In Patients With Systemic Lupus Erythematosus Increases Sensitivity For Detecting Asymptomatic Atherosclerosis (2013) (0)
Raised Arterial Pressure and Microalbuminuria in Type 2 Diabetic Subjects with Familial Hypertension (2016) (0)
Book Review A Color Handbook of Rheumatology Ted R Mikuls, Amy C Cannella, Gerald F Moore, James R O'Dell, Alan R Erickson, Geoffrey M Thiele Manson Publishing 2013 £29.95. Pp 224 ISBN 978 1 84076 173 3 (2013) (0)
Rheumatic diseases and musculoskeletal pain (2018) (0)
BILAG BIOLOGICS PROSPECTIVE COHORT: THE USE OF NOVEL BIOLOGICAL THERAPIES IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN THE UNITED KINGDOM (2012) (0)
Ageing and the Musculoskeletal SystemI75. Musculoskeletal Ageing: From Epidemiology to Clinical Trials (2013) (0)
NITRATED NUCLEOSOME LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ASSOCIATIONS WITH ETHNICITY, AUTOANTIBODY STATUS AND ETHNICITY (2012) (0)
Cultured endothelial cells produce microparticles when stimulated with human polyclonal and monoclonal IgG antiphospholipid antibodies (2008) (0)
Elucidating the immunodominant binding epitopes recognised by pathogenic antiphospholipid antibodies using mutational studies. (2005) (0)
THU0318 The Pregnancy Experience of 85 Women with SLE Followed in A Specialist Lupus Clinic Compared To The General Population (2016) (0)
The BILAG-2004 Systems Tally-a Novel Way of Analysing the BILAG-2004 Scores (2011) (0)
1107 Economic evaluation of hydroxychloroquine use in an international inception cohort (2021) (0)
Antiphospholipid Antibody on Its In Vivo Sequence Changes in a Human Monoclonal Thrombin Binding Predicts the Effects of (0)
STATINS AND HYDROXYCHLOROQUINE CAN PREVENT THE PROCOAGULANT/THROMBOGENIC PROPERTIES OF ANTIPHOSPHOLIPID ANTIBODIES IN MONOCYTES (2009) (0)
Immediate Impact of Kidney Transplantation on Blood Pressure – Single Center Experience (2016) (0)
Economic Evaluation of Damage Accrual in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2017) (0)
Sequence features of monoclonal antiphospholipid antibodies: comment on the article by Ikematsu et al. (1999) (0)
Sequence motifs in human monoclonal antiphospholipid antibodies have differential effects on the activation of certain signalling pathways that do not always mirror their binding effects (2008) (0)
CHARACTERISTICS OF PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS REQUIRING BIOLOGIC THERAPY IN A UK MULTICENTRE COHORT (2013) (0)
PS8:157 Identifying the rates of iron deficiency and anaemia in patients with systemic lupus erythematosus (2018) (0)
Use of an in-vitro expression system to assess the role played by arginines in determining the ability of different human antiphospholipid antibody derived heavy and light chain combinations to bind to cardiolipin. (2002) (0)
Preliminary Rasch analysis of SLEDAI-2000 index: An ordinal scale index with internal construct validity (2006) (0)
Patients with SLE Who Are Anti-Factor Xa IgG Positive Are Less Likely to Have Atherosclerotic Plaque (2015) (0)
Arginine residues are critical in the binding of human monoclonal antiphospholipid antibodies to beta 2glycoprotein I (2005) (0)
The critical role of arginine residues in the binding of human monoclonal antiphospholipid antibodies to beta 2glycoprotein I. (2004) (0)
Arginine residues in human monoclonal antiphospholipid antibodies are important in determining their ability to bind and affect the function of antigens relevant to the pathogenesis of atherosclerosis in the antiphospholipid syndrome (2007) (0)
Is the Disease-Specific Lupusqol Sensitive to Changes of Disease Activity in SLE Patients after Treatment of a Flare? (2014) (0)
Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register (2015) (0)
S15.2 Severe non-adherence to hydroxychloroquine is associated with flares, early damage, and mortality in systemic lupus erythematosus: data from 660 patients from the slicc inception cohort (2022) (0)
S6D:5 Antiphospholipid antibodies differentially regulate the expression & activity of the lysosomal proteases with effects upon monocyte autophagy (2018) (0)
Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study. (2014) (0)
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor (2017) (0)
Crohn's Disease and Diagnostic Difficulty: A Case Report (2018) (0)
Diseases Leaders Does it take sugar ? A clinical role for measuring the glycosylation of IgG ? ' Does He (0)
AB0131 Platelet microparticles (PMPS) are higher in patients with SLE compared to healthy controls (2017) (0)
I09. TREAT TO TARGET IN LUPUS (2017) (0)
OP-BRHE200783 3262..3267 (2021) (0)
List of Contributors (2019) (0)
Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model (2015) (0)
Decreased Live Births in Women with SLE (2010) (0)
Sequence motifs in human monoclonal antiphospholipid antibodies have differential effects on the in vitro production of endothelial microparticles that are not always predicted by their binding properties (2008) (0)
P173 Progression of subclinical cardiovascular disease in SLE: a five year follow up study (2020) (0)
SAT0419 Renal and overall survival analysis in a cohort of patients with lupus nephritis with up to 40 years of follow up (2018) (0)
Editorial Systemic Lupus Erythematosus: Genomics, Mechanisms, and Therapies (2012) (0)
A Study of Lipid Profile and Glycosylated Haemoglobin in Hypertensive (2013) (0)
O29 PEGYLATED RECOMBINANT DOMAIN I OF beta-2-GLYCOPROTEIN I, A POTENTIAL THERAPEUTIC AGENT FOR ANTI-PHOSPHOLIPID SYNDROME, FULLY RETAINS ITS ABILITY TO INHIBIT BINDING OF IGG OR IGA ANTIBODIES FROM PATIENTS WITH ANTI-PHOSPHOLIPID SYNDROMEAPS TO beta-2-GLYCOPROTEIN GPI IN VITRO (2016) (0)
CE-10 Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (0)
PS5:99 Examining the modulatory effects of anti-serine protease antibodies upon factor xa, thrombin and complement interactions (2018) (0)
BSPAR ANNUAL CONFERENCE ABSTRACTSOral presentationsO1. The impact of modern management on outcomes of JIA compared with healthy controls (2012) (0)
A young woman with SLE: diagnostic and therapeutic challenges. (1997) (0)
Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function (2012) (0)
Polyclonal igg from patients with the APS stimulate the production of endothelial microparticles in an in vitro assay (2008) (0)
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes (2023) (0)
Systematic review of sequences of human antiphospholipid and anti-beta 2 glycoprotein I antibodies (aPL). (2003) (0)
Exploring the nature of the interaction between human monoclonal antiphospholipid antibodies and Domain I of beta-2-glycoprotein I (2006) (0)
SLE and antiphospholipid syndrome Friday , 22 April 2005 i 135 SLE and antiphospholipid syndrome 336 (2005) (0)
A Comparison of Allograft Survival Between Cyclosporine and Tacrolimus Based Immunosuppressive Therapy in Kidney Transplantation: BIRDEM General Hospital Experience (2016) (0)
801 Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk (2021) (0)
OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT (2021) (0)
BILAG-2004 captures SLE disease activity better than SLEDAI-2000 (2005) (0)
EFFECTS OF RITUXIMAB ON DISEASE ACTIVITY, PULMONARY FUNCTION AND HEALTH STATUS IN SLE PATIENTS (2007) (0)
Effects of Vitamin D Deficiency- An Update (2019) (0)
A Paper Patient-Based Flare Study in SLE (2015) (0)
A novel, efficient prokaryotic expression system of domain I of human beta2 glycoprotein I. (2004) (0)
The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study (2015) (0)
POS0705 BILAG-2004 INDEX ACTIVE DISEASE PREDICTS DEVELOPMENT OF DAMAGE (2021) (0)
A Prospective Study of Seizures in Systemic Lupus Erythematosus. (2011) (0)
Third Trimester Placental Grading by Ultrasonography and its Relationship with Fetal Outcome (2020) (0)
Different Patterns of Positivity for IgG Anti-Cardiolipin, Anti-Beta-2-Glycoprotein I and Anti-Domain I Antibodies within the First Year of Disease in 501 Patients with SLE - Associations with Different Clinical Outcomes (2015) (0)
321. Trends in the Lupusqol Following Treatment of a Flare in Patients with Systemic Lupus Erythematosus (2014) (0)
I41 Invariant Naurural Killer T Cells: A New Player in the Pathogenesis of Atherosclerosis in Patients with Systemic Lupus Erythematosus (2016) (0)
ANTI-FACTOR XA ANTIBODIES ARE SIGNIFICANTLY INCREASED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME (2012) (0)
I059 Atherosclerosis in lupus: can early detection be achieved and acted upon? (2019) (0)
Chronic widespread pain : North and South Are the factors similar in both developed and developing countries ? (0)
S7D:6 Going viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about research in sle and aps (2018) (0)
Do high-sensitivity C-reactive protein levels help predict risk of cardiovascular disease in patients with osteoarthritis? (2008) (0)
Signaling Pathways Antiphospholipid Syndrome on Monocyte Patients with Different Clinical Types of the Effects of Polyclonal IgG Derived from (2010) (0)
141 Evaluating the prevalence of heavy menstrual bleeding (menorrhagia) in patients with systemic lupus erythematosus (2018) (0)
A Systematic Analysis Confirms the Importance of Toll-Like Receptor 4, p38 Mitogen Activated Protein Kinase and Nuclear Factor Kappa-B Activation by Antiphospholipid Antibodies in Multiple Different Cell Types (2011) (0)
Birmingham Construction of a frailty index as a novel health measure in systemic lupus erythematosus (2019) (0)
BHPR: Audit and Clinical Evaluation103. Dental Health in Children and Young Adults with Inflammatory Arthritis: Access to Dental Care (2013) (0)
Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study (2020) (0)
324. Factor-Xa-Reactive Antibodies in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome Have Differential Effects on Coagulation Assays (2014) (0)
Molecular cloning. Expression and functional evaluation of the recombinant Fabs of human anti-DNA (B3) and anti-cardiolipin (UK4) antibodies and their hybrids. (1999) (0)
A Case Report on En Caul Delivery of Extremely Preterm Fetus (2020) (0)
Incorrect Values for Intractable and Cluster Headaches at Enrollment Shown in Figure 1 and Incorrect Prevalence of Headache at Ten Years in Text of the Article by Hanly et al (Arthritis Rheum, November 2013) (2014) (0)
252 Examining the modulatory effects of anti-serine protease antibodies upon factor Xa, thrombin and complement interactions (2018) (0)
A NOVEL ASSAY FOR DETECTING NITRATED NUCLEOSOMES: A POTENTIAL SURROGATE BIOMARKER FOR JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (2012) (0)
102 M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort (2022) (0)
Anti-Nucleosome Antibodies Are Associated with Disease Activity and Hydroxychloroquine Use in Patients with Lupus: A Longitudinal, Multivariate Analysis of 398 Samples. (2012) (0)
E088 Antiphospholipase A2 receptor antibodies, a marker of idiopathic membranous nephropathy, are not present in membranous lupus nephritis (2019) (0)
Pac-Man Method: A New Technique for Nuclear Management Of Posterior Polar Cataract (2021) (0)
Antilipoprotein and Antiendothelial Cell Antibodies (2019) (0)
Could cardiac magnetic resonance imaging have a role in the management of patients with systemic lupus erythematosus (2008) (0)
P20 Scleritis as initial presenting feature in ANCA-associated vasculitis (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Anisur Rahman?

Anisur Rahman is affiliated with the following schools:

Anisur Rahman's Academic­Influence.com Rankings

Anisur Rahman's Degrees

Similar Degrees You Can Earn

Why Is Anisur Rahman Influential?

Anisur Rahman's Published Works

Published Works

What Schools Are Affiliated With Anisur Rahman?

Anisur Rahman's AcademicInfluence.com Rankings